Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Multiple Sclerosis

Immune System Diseases

The study will investigate immune cell subsets, and how the cells are modified by this therapy over a 1-year period in 25 subjects. Blood will be drawn at baseline, 2 weeks, 6 mo, and 12 mo.

Immune subsets will be analyzed by flow cytometry. Data are analyzed with ANOVA with repeated measures.

ocrelizumab

measured through lymphocyte surface marker stains, from patients, before and after ocrelizumab (Ocrevus) therapy Mononuclear cells (MNC) will be stained, for flow cytometry, with marker antibodies to B cells.

The change in the percentage of each subset will be compared before and after treatment with paired t tests and ANOVA.

ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start

age- and sex-matched untreated MS controls

age- and sex-matched untreated healthy controls

University of Chicago

ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start

ocrelizumab: FDA-approved MS drugs

MS-ocrelizumab Treated

MS Untreated

Healthy Control

MS Interferon-treated

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

Race (NIH/OMB)

United States

Region of Enrollment

anthony t reder

ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start

ocrelizumab: FDA-approved MS drugs

all enrolled

age- and sex-matched untreated MS controls

all enrolled

age- and sex-matched untreated healthy controls

all enrolled

MS with ongoing interferon-beta therapy

all enrolled

The MS-ocrelizumab treated group was analyzed for depletion of B cells, whereas MS-untreated, healthy controls and MS interferon-treated groups were not analyzed for depletion of B cells.

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

About this trial

Study ID

Status

Type

Placebo

Accepting

Trial Timing

What is this trial about?

What are the participation requirements?